Erasca Inc ERAS

$15.66 -0.12 (-0.76%)

Valuation

Market cap
5,477,273,000
Revenue TTM
$0
Net income TTM
$-124,550,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
8,533,400
Avg volume
5,164,350
Day's range
$14.12 – $15.84
Shares out
349,762,000
Stochastic %K
60%
Beta
0.68
Analysts
Moderate Buy
Price target
$23.70

Price

Company profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12,...

Show more

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 465 6511
Website
https://www.erasca.com
Address
3115 Merryfield Row, Suite 300, San Diego, United States

Latest news

Stocktwits

FlashSigma Nov 15, 4:17 AM
$ERAS quietly holding attention here. Not a ton of noise but the chart action says someone's paying attention. Feels like a wait-and-see setup right now. Watching how it behaves around current levels before reading too much into it.
0 replies
Alt_Fuel Nov 13, 12:46 PM
$VSTM $RVMD $TNGX $ERAS Positioning relative to the highlighted shift Verastem’s strategy aligns with Doepke’s view that combinations are the way forward: strong single-agent activity with a selective G12D inhibitor (potentially preferred for that large subgroup over pan-RAS agents due to selectivity/tolerability) plus deliberate combo trials in 1L and later lines. Analysts have noted its [ Verastems] data as competitive or superior in the G12D subset compared with pan-RAS agents like daraxonrasib in certain cross-trial views. Doepke himself has posted positively on the VS-7375 updates (including the 50% 2L ORR and Phase 3 plans) in the context of RVMD and ERAS. Verastem is one of several companies (alongside Revolution, Tango, Erasca, and others) driving this RAS-focused, combination-heavy wave in PDAC. Cash position was strengthened by a recent $250M offering, supporting continued development. https://x.com/i/grok?conversation=2121221416158720203
0 replies
shoc24 Nov 13, 12:27 AM
$ERAS reported earnings after the close today. GAAP EPS missed estimates: -$0.15 vs. -$0.13 expected, according to Stock Meadow.
0 replies
d_risk Nov 12, 9:20 PM
$ERAS - Erasca, Inc. - 10Q - Updated Legal Disclosure Erasca says a court named lead plaintiffs in its securities case and stayed the derivative case pending resolution. #legaldisclosure #secfilings 🟢 Added 🟠 Removed https://d-risk.ai/ERAS?filing=NZMYONo6WTyMHJhW4cFbD#legal-filing-comparison
0 replies
terry9 Nov 12, 1:31 PM
$ERAS I thought earnings was yesterday
1 replies
PhishTourFunds Nov 12, 2:39 AM
$ERAS Better than 2x daily average volume here today ~ shorts are absolutely loaded to the gills 👀
0 replies
Arcides Nov 12, 1:00 AM
$ERAS high volume today...no news
0 replies
red_bull7 Nov 11, 11:49 PM
$ERAS Expecting a nice run up with Fast Tracked Cancer Drug Data readout later this month. $SPY $RVMD $BBOT
0 replies